# Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

> **NCT02623010** · PHASE2 · UNKNOWN · sponsor: **Rabin Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Imbruvica

## Key facts

- **NCT ID:** NCT02623010
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623010, "Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02623010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*